Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ONO-2333Ms Experimental 2 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Experimental 1 | EXPERIMENTAL | 1-2 mg of ONO-2333 |
| Experimental 2 | EXPERIMENTAL | 5-10 mg of ONO-2333 |
| Placebo | PLACEBO_COMPARATOR | placebo comparator |
| Name | Type | Description |
|---|---|---|
| ONO-2333Ms Experimental 2 | DRUG | 5-10 mg QD(once a day) for 8 weeks |
| Placebo | DRUG | 0 mg QD(once a day) for 8 weeks |
| ONO-2333Ms Experimental 1 | DRUG | 1-2 mg QD(once a day) for 8 weeks |
Inclusion Criteria: * Diagnosed with recurrent major depressive disorder Exclusion Criteria: * Patients with treatment resistance for depression * History of alcohol abuse/dependence, substance abuse/dependence within 6 months * Has clinically significant unstable medical condition * Has signific...
Top 20 of 29 competitors
ONO-2333Ms Experimental 2 is an investigational small molecule being studied for the treatment of Major Depressive Disorder. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
ONO-2333Ms Experimental 2 is being developed by BrainsWay Ltd., a company traded on the stock exchange under the ticker BWAY. The drug is in Phase 2 clinical trials for Major Depressive Disorder.
ONO-2333Ms Experimental 2 is in Phase 2 clinical development. It is an investigational drug and has not been approved for any use. A Phase 2 trial for the drug has been completed.
ONO-2333Ms Experimental 2 has one completed clinical trial, identified as NCT00514865. This was a Phase 2, placebo-controlled, double-blind, randomized study in patients with recurrent Major Depressive Disorder, conducted in the United States with 278 participants.
ONO-2333Ms Experimental 2 is also known by the name ONO-2333Ms. The drug is being studied under this name in clinical trials for Major Depressive Disorder.